Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Sort by
Order
Filters
Sort by
Order
Sort by
Order
Results (385)
Sort by:
RILPL2 Antibody (Ms)
Antibody
Rabbit monoclonal antibody directed against mouse RILPL2 for immunoblotting, immunostaining, and immunoprecipitation applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative
  • RILPL2
Rab 12 pS106 Phosphospecific Antibody (WB/PRM-MS)
Antibody
Rabbit monoclonal antibody directed against human Rab12 when phosphorylated at Serine106 (pS106 Rab12). Developed for use in immunoblot and PRM-MS applications. 
  • Rab
SNCA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SNCA, including
  • -A30P (heterozygous and homozygous)
  • -A53T (heterozygous and homozygous)
  • -E46K (heterozygous and homozygous)
  • -DOX-NGN2 + TMEM192-HA + A53T (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative
  • SNCA
SNCA A53T Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with SNCA A53T mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 
  • Alpha-Synuclein
SNCA A30P Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with SNCA A30P mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 
  • Alpha-Synuclein
LRRK2 G2019S Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with LRRK2 G2019S mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
  • LRRK2
DJ-1 Exon 1-5 Deletion Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with DJ-1 Exon 1-5 deletion. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 
  • DJ-1
GBA IVS2+1 Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with GBA IVS2+1 mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 
  • GBA
Parkin Exon 3 Deletion Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with PRKN Exon 3 deletion. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative.
  • PRKN
PINK1 Q129X Human ES Cell Line
Immortalized Cell
Modified WIBR3 Human ES cell line with PINK1 Q129X mutation. This line was generated as part of the iSCORE-PD (Isogenic Stem Cell Collection to Research Parkinson’s Disease) collection created through a collaboration between the Soldner Lab, Albert Einstein College of Medicine, Hockemeyer Lab, University of California, Berkeley, Bateup Lab, University of California, Berkeley, and Rio Lab, University of California, Berkeley, and developed under the Aligning Science Across Parkinson’s (ASAP) initiative. 
  • PINK1
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.